Pharmacogenomics: Ethical concerns for research and pharmacy practice

American Journal of Health-System Pharmacy

Volumn 59, Issue 22, 2002, Pages 2239-2240

  Alcalde, M Gabriela ^a   Rothstein, Mark A ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL PHARMACY; CLINICAL PRACTICE; DRUG INDUSTRY; DRUG RESEARCH; INFORMED CONSENT; LAW; MEDICAL ETHICS; METHODOLOGY; NOTE; PATIENT RIGHT; PHARMACOGENOMICS; PRIORITY JOURNAL;

EID: 0037111783     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/59.22.2239     Document Type: Note

References (5)

1. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report. www.ohrp.osophs.dhhs.gov/humansubjects/guidance/belmont.htm (accessed 2002 Aug 6).
2. National Institutes of Health. Federal Policy for the Protection of Human Subjects (Codified at 45 CFR 46). www.ohrp.osophs. dhhs.gov/humansubjects/guidan ce/ 45cfr46.htm (accessed 2002 Aug 6).
3. Rothstein MA, Epps PG. Ethical and legal implications of pharmacogenomics. Nat Rev Genet. 2001;2:228-31.
4. Brushwood DB. Pharmacogenomics and pharmacy practice. In: Rothstein MA, ed. Pharmacogenomics: Social, Ethical and Clinical Dimensions. New York: Wiley; in press.
5. Ibid. In press.